Article Text
Abstract
Aortic stenosis is the most common adult heart valve condition seen in the Western world and its incidence continues to rise. No established disease modifying treatments retard progression of the stenotic process. Recent insights into the pathogenesis of calcific aortic stenosis suggest that the disease mimics atherosclerosis. The natural history and progression of calcific aortic stenosis are described with particular emphasis on new and emerging medical treatments that may modify the disease process. In particular, statins and angiotensin converting enzyme inhibitors appear to hold promise but definitive evidence from large clinical trials is awaited.
- ACE, angiotensin converting enzyme
- ASTRONOMER, aortic stenosis progression observation: measuring effect of rosuvastatin
- LDL, low density lipoprotein
- SALTIRE, Scottish aortic stenosis and lipid lowering therapy, impact on regression
- SEAS, simvastatin and ezetimibe in aortic stenosis
- aortic stenosis
- angiotensin converting enzyme inhibitors
- statins
Statistics from Altmetric.com
Footnotes
-
Conflicts of interest declaration: The authors were involved in the SALTIRE trial funded by the British Heart Foundation with an additional educational grant award from Pfizer (UK) Limited and are participating in the SEAS study, which is sponsored by Merck Sharp and Dohme Limited.
Linked Articles
- Miscellanea
- Miscellanea
- Miscellanea